Kurs
+6,41%
Kalender
Est. tid* | ||
2024-02-29 | - | Bokslutskommuniké 2023 |
2023-11-23 | - | Kvartalsrapport 2023-Q3 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-06-30 | - | Årsstämma |
2023-05-31 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2023-02-28 | - | Bokslutskommuniké 2022 |
2023-02-09 | - | Extra Bolagsstämma 2022 |
2022-11-24 | - | Kvartalsrapport 2022-Q3 |
2022-08-26 | - | Kvartalsrapport 2022-Q2 |
2022-05-20 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2022-05-19 | - | Årsstämma |
2022-05-11 | - | Kvartalsrapport 2022-Q1 |
2022-02-25 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-07-16 | - | Kvartalsrapport 2021-Q2 |
2021-06-17 | - | Årsstämma |
2021-05-27 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2021-05-07 | - | Kvartalsrapport 2021-Q1 |
2021-02-10 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-07-17 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-15 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-15 | - | Kvartalsrapport 2019-Q3 |
2019-08-19 | - | Extra Bolagsstämma 2019 |
2019-08-15 | - | Kvartalsrapport 2019-Q2 |
2019-05-31 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2019-05-29 | - | Årsstämma |
2019-05-15 | - | Kvartalsrapport 2019-Q1 |
2019-02-28 | - | Bokslutskommuniké 2018 |
2018-11-30 | - | Kvartalsrapport 2018-Q3 |
2018-08-31 | - | Kvartalsrapport 2018-Q2 |
2018-06-14 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2018-06-13 | - | Årsstämma |
2018-05-31 | - | Kvartalsrapport 2018-Q1 |
2018-02-28 | - | Bokslutskommuniké 2017 |
2017-11-28 | - | Kvartalsrapport 2017-Q3 |
2017-11-15 | - | Extra Bolagsstämma 2017 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-06-09 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2017-06-08 | - | Årsstämma |
2017-05-31 | - | Kvartalsrapport 2017-Q1 |
2017-02-20 | - | Bokslutskommuniké 2016 |
2016-11-30 | - | Kvartalsrapport 2016-Q3 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
2016-06-01 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2016-05-31 | - | Årsstämma |
2016-05-31 | - | Kvartalsrapport 2016-Q1 |
2016-02-29 | - | Bokslutskommuniké 2015 |
2016-01-21 | - | Extra Bolagsstämma 2016 |
2015-11-30 | - | Kvartalsrapport 2015-Q3 |
2015-08-31 | - | Kvartalsrapport 2015-Q2 |
2015-06-12 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2015-06-11 | - | Årsstämma |
2015-05-28 | - | Kvartalsrapport 2015-Q1 |
2015-02-27 | - | Bokslutskommuniké 2014 |
2014-11-28 | - | Kvartalsrapport 2014-Q3 |
2014-09-12 | - | Extra Bolagsstämma 2014 |
2014-08-29 | - | Kvartalsrapport 2014-Q2 |
2014-06-10 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2014-06-09 | - | Årsstämma |
2014-05-23 | - | Kvartalsrapport 2014-Q1 |
2014-03-05 | - | Bokslutskommuniké 2013 |
2013-11-29 | - | Kvartalsrapport 2013-Q3 |
2013-09-04 | - | Kvartalsrapport 2013-Q2 |
2013-05-31 | - | Kvartalsrapport 2013-Q1 |
2013-05-08 | - | Split RLS 10:1 |
2013-04-11 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2013-04-10 | - | Årsstämma |
2013-03-05 | - | Bokslutskommuniké 2012 |
2012-11-26 | - | Kvartalsrapport 2012-Q3 |
2012-08-31 | - | Kvartalsrapport 2012-Q2 |
2012-06-12 | - | X-dag ordinarie utdelning RLS 0.00 SEK |
2012-06-11 | - | Årsstämma |
Beskrivning
Land | Sverige |
---|---|
Sektor | Hälsovård |
Industri | Medicinteknik |
As of 11[th] of July 2022, ChloraSolv is available in the UK to NHS (National Health Service) organizations who purchase from NHS Supply Chain or directly from ConvaTec. ChloraSolv is available to all NHS facilities who have an account at NHS Supply Chain. It is applicable to a range of settings, including hospitals as well as primary and home care settings. ChloraSolv also can be purchased directly from ConvaTec, RLS' exclusive distribution partner for ChloraSolv in Europe.
ChloraSolv's inclusion on the NHS Supply Chain advanced wound care framework is the first step to enabling access to the UK market. In parallel, RLS and ConvaTec are working together to provide broader access to ChloraSolv across the UK, through additional routes to market.
Karin Fischer, CEO, RLS Global, says: "The UK is a strategic important market for advanced wound care and we are delighted to build on our strategic partnership with ConvaTec to bring this solution to the NHS."
RLS, together with ConvaTec, have worked to evaluate the technology and collect relevant data to secure approved access to the NHS Supply Chain. Wound debridement supports faster healing of wounds and is a fundamental part of wound management. It reduces the negative impact from hard to heal wounds on patients' quality of life. It also reduces the healthcare resources needed to support patients.
ChloraSolv is a new innovative option for wound cleansing and debridement/desloughing and reducing microbiological load. It is a unique gel application, intended for use in adult patients with chronic leg ulcers and diabetic foot ulcers in need of debridement.
ChloraSolv provides a convenient, effective and gentle option for debridement.
THIS IS CHLORASOLV:
ChloraSolv is a debriding gel, based on a unique hypochlorite technology, which is used with very good effect on leg ulcers and diabetic foot ulcers. The gel allows the gentle removal of devitalised tissue and promotes natural wound healing.[1] ChloraSolv does not damage healthy tissue and is well tolerated by the patient.
1. Eliasson B, Fagerdahl AM, Jönsson A, Apelqvist J. An open single arm multicenter pilot investigation to evaluate the debriding effect of amino acid buffered hypochlorite (ChloraSolv®) on chronic wounds covered with devitalized tissue during six weeks treatment. Journal of Wound Care (Accepted for publication).
RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17[th] May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. Duringthe period 2012-2017, the company was listed on Aktietorget.
FOR MORE INFORMATION, PLEASE CONTACT:
Karin Fischer, CEO, RLS Global
E-mail: karin.fischer@rlsglobal.se
Tel: +46 702 48 46 51